Key result
Urotensin II infusion in hyperlipidemic rabbits increased atherosclerotic plaque size by 69% over control and delayed plaque regression.
Why the study?
Elevated urotensin II (UII) levels are associated with cardiovascular diseases, but its role in the initiation, progression, and regression of atherosclerosis remains to be verified.
Does urotensin II infusion accelerate atherosclerosis formation and delay plaque regression in hyperlipidemic rabbits?
Does urotensin II infusion accelerate atherosclerosis formation and delay plaque regression in hyperlipidemic rabbits?
Urotensin II accelerates aortic and coronary plaque formation, enhances plaque vulnerability, and delays atherosclerosis regression in hyperlipidemic rabbits, partly through pro-angiogenic effects.
UII may accelerate atherosclerosis in hyperlipidemic models; leaves open its role in human plaque progression and regression.
Accumulated evidence shows that elevated urotensin II (UII) levels are associated with cardiovascular diseases. However, the role of UII in the initiation, progression, and regression of atherosclerosis remains to be verified. Different stages of atherosclerosis were induced in rabbits by a 0.3% high cholesterol diet (HCD) feeding, and either UII (5.4 μg/kg/h) or saline was chronically infused via osmotic mini-pumps. UII promoted atherosclerotic fatty streak formation in ovariectomized female rabbits (34% increase in gross lesion and 93% increase in microscopic lesion), and in male rabbits (39% increase in gross lesion). UII infusion significantly increased the plaque size of the carotid and subclavian arteries (69% increase over the control). In addition, UII infusion significantly enhanced the development of coronary lesions by increasing plaque size and lumen stenosis. Histopathological analysis revealed that aortic lesions in the UII group were characterized by increasing lesional macrophages, lipid deposition, and intra-plaque neovessel formation. UII infusion also significantly delayed the regression of atherosclerosis in rabbits by increasing the intra-plaque macrophage ratio. Furthermore, UII treatment led to a significant increase in NOX2 and HIF-1α/VEGF-A expression accompanied by increased reactive oxygen species levels in cultured macrophages. Tubule formation assays showed that UII exerted a pro-angiogenic effect in cultured endothelial cell lines and this effect was partly inhibited by urantide, a UII receptor antagonist. These findings suggest that UII can accelerate aortic and coronary plaque formation and enhance aortic plaque vulnerability, but delay the regression of atherosclerosis. The role of UII on angiogenesis in the lesion may be involved in complex plaque development.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2023) studied Atherosclerosis. Urotensin II (UII) vs. Saline was evaluated on Atherosclerotic fatty streak formation and plaque size. Urotensin II infusion in hyperlipidemic rabbits increased atherosclerotic plaque size by 69% over control and delayed plaque regression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: